| Literature DB >> 1509305 |
M P Mölken1, E K Van Doorslaer, F F Rutten.
Abstract
Despite the considerable burden and costs of illness and despite the increasing need to set priorities on the basis of efficiency considerations, only 20 economic appraisals of asthma and COPD care have been published during the past 11 years. This paper provides a detailed summary of the cost-effectiveness 'evidence' given by these studies and a discussion of relevant methodological issues. The studies comparing programme costs of delivery methods for oxygen and for aerosol bronchodilator drugs, provide the most straightforward evidence in favour of the concentrator and the metered dose inhaler respectively. There also seems to be evidence in favour of hospital-based home care programmes as compared to community-based home care programs. Health education, especially directed at asthmatic children seems to reduce health care costs and improve attitude, compliance behaviour and self-management skills. Information on the cost-effectiveness of pharmacotherapy and diagnostic technologies, both important interventions in asthma and COPD, was found to be totally lacking.Entities:
Mesh:
Year: 1992 PMID: 1509305 DOI: 10.1016/0277-9536(92)90163-k
Source DB: PubMed Journal: Soc Sci Med ISSN: 0277-9536 Impact factor: 4.634